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Abnormally invasive placenta (AIP) is a clinical term
used to describe a placenta that does not separate
spontaneously at delivery and cannot be removed without
causing abnormally high blood loss1. It encompasses the
histopathological diagnoses of placenta accreta, placenta
increta and placenta percreta. It is a spectrum disorder,
ranging from placentae containing a small area of
abnormally adherent tissue (focal accreta) to those which
have invaded into the adjacent viscera (percreta). It is
potentially life-threatening, as forced removal of an AIP
can lead to catastrophic maternal hemorrhage2,3.
In developed countries, AIP is the most common reason
cited for Cesarean hysterectomy4. Maternal mortality
for the most severe end of the AIP spectrum (placenta
percreta) has been reported to be as high as 7%5, although
this information was published in 1996 and may now
be an overestimate given the advances in perinatal care
and facilities. Prior Cesarean section (CS), other uterine
surgery, assisted reproduction techniques and placenta
previa are all risk factors for AIP and their prevalence
has increased steadily over the last few decades6–8. The
incidence of AIP has increased from 1:25 000 in the 1950s
to 1:25008,9 in the 1980s, paralleling the rise in CS
rates, and AIP rates as high as 1:533 (USA)7 and 1:588
(Canada)10 have been reported recently. If these trends
continue, it has been estimated that, by 2020, the USA
will have a 56% CS rate, accounting for an additional
4504 cases of AIP and 130 maternal deaths annually11.
Maternal mortality and morbidity are reduced when
AIP is diagnosed antenatally and women deliver in
a tertiary care hospital with a multidisciplinary care
team12–14. Currently, diagnosis relies on ‘typical’ sono-
graphic findings15,16, such as ‘placental lacunae’ and ‘loss
of the retroplacental clear zone’17. Magnetic resonance
imaging, although employed widely in cases of suspected
AIP, has yet to be demonstrated clearly to improve man-
agement or pregnancy outcome15. Irrespective of the
imaging modality, diagnosis of AIP is subjective, with
accuracy depending on the training and level of experience
of the operator.
Several studies have assessed the predictive value
of different ultrasound markers of AIP. However,
the performance of these markers shows considerable
variability among studies using the same signs16.
These differences have been attributed previously to a
combination of limited sample size, retrospective design
and variability of study inclusion criteria and eventual
diagnosis of AIP16. Furthermore, as with all diagnostic
techniques reliant on subjective opinion, the recorded
presence or absence of each sign will be influenced by the
operator’s interpretation of what constitutes that marker.
This is particularly important to clinicians, who may
not have much experience with ultrasonography of the
placenta or diagnosing AIP. Additionally, there is no
published consensus on the definition of the ultrasound
markers used commonly for AIP. Many signs have been
described under different names, and in other cases the
same term has been used for different findings. The aim of
our study, therefore, was to provide unified definitions of
ultrasound markers used commonly for AIP (‘ultrasound
descriptors of AIP’).
The ‘European Working Group on Abnormally
Invasive Placenta’ (www.EW-AIP.org) is an international
non-profit group, currently consisting of 29 obstetricians,
gynecologists, pathologists, anesthesiologists and basic
science researchers from 11 European countries. The aim
of the group is to advance diagnosis and treatment and
to promote research and knowledge on AIP. To improve
comparability of future studies, to increase diagnostic
capabilities and to facilitate international collaboration,
the EW-AIP here proposes standardized definitions of the
AIP imaging descriptors.
These standardized definitions were produced by
analysis of all 23 studies included in a recent systematic
review of the antenatal sonographic diagnosis of
AIP16 (Appendix S1). The exact wording used to
describe the ultrasound signs of AIP was extracted,
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Table 1 Unified descriptors, as suggested by the European Working Group on Abnormally Invasive Placenta (EW-AIP), for ultrasound (US)
findings in AIP
US finding EW-AIP suggested standardized definition
2D grayscale
Loss of ‘clear zone’ (Figure 1) Loss, or irregularity, of hypoechoic plane in myometrium underneath placental bed
(‘clear zone’)
Abnormal placental lacunae (Figure 2) Presence of numerous lacunae including some that are large and irregular (Finberg
Grade 3), often containing turbulent flow visible on grayscale imaging
Bladder wall interruption (Figure 3) Loss or interruption of bright bladder wall (hyperechoic band or ‘line’ between uterine
serosa and bladder lumen)
Myometrial thinning (Figure 4) Thinning of myometrium overlying placenta to <1 mm or undetectable
Placental bulge (Figure 5) Deviation of uterine serosa away from expected plane, caused by abnormal bulge of
placental tissue into neighboring organ, typically bladder; uterine serosa appears
intact but outline shape is distorted
Focal exophytic mass (Figure 6) Placental tissue seen breaking through uterine serosa and extending beyond it; most
often seen inside filled urinary bladder
2D color Doppler
Uterovesical hypervascularity (Figure 7) Striking amount of color Doppler signal seen between myometrium and posterior wall
of bladder; this sign probably indicates numerous, closely packed, tortuous vessels in
that region (demonstrating multidirectional flow and aliasing artifact)
Subplacental hypervascularity (Figure 8) Striking amount of color Doppler signal seen in placental bed; this sign probably
indicates numerous, closely packed, tortuous vessels in that region (demonstrating
multidirectional flow and aliasing artifact)
Bridging vessels (Figure 9) Vessels appearing to extend from placenta, across myometrium and beyond serosa into
bladder or other organs; often running perpendicular to myometrium
Placental lacunae feeder vessels (Figure 10) Vessels with high-velocity blood flow leading from myometrium into placental lacunae,
causing turbulence upon entry
3D ultrasound± power Doppler
Intraplacental hypervascularity (Figure 11) Complex, irregular arrangement of numerous placental vessels, exhibiting tortuous
courses and varying calibers
Placental bulge (as in 2D)
Focal exophytic mass (as in 2D)
Uterovesical hypervascularity (as in 2D)
Bridging vessels (as in 2D)
2D, two-dimensional; 3D, three-dimensional.
No hypoechoic plane Hypoechoic plane
Figure 1 Loss of the ‘clear zone’ (a) and a normal example for
comparison (b) on grayscale ultrasound.
the descriptions were grouped according to ultrasound
modality (two-dimensional (2D) grayscale ultrasound, 2D
color Doppler and three-dimensional (3D) ultrasound)
and synonymous or identical terms were unified under
a common heading (Table S1). Following discussion by
an expert panel (EW-AIP members present at the 7th
EW-AIP meeting in Nancy, November 2014) the various
wordings were unified into a set of 11 descriptors, six for
2D grayscale ultrasound, four for 2D color Doppler and
one for 3D power Doppler (Table 1). The occurrence of
each descriptor in the 23 papers used, grouped according
to ultrasound modality, are listed in Table S2. Four
of the papers18–21 included descriptions considered by
the expert panel to be insufficiently comprehensive or
specific and were not included in the unifying descriptors.
Figure 2 Abnormal placental lacunae (a,b) and normal examples
for comparison (c,d) (calipers) on grayscale ultrasound.
Compound signs (e.g. ‘uterovesical hypervascularity AND
bridging vessels’) were divided and included in the
individual descriptors.
During the meeting in Nancy, and in the following
discussions among all EW-AIP members, importance was
placed on defining each sign unambiguously, irrespective
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Interruption in
bladder wall
Interruptions
in bladder wall
Smooth line of
bladder wall
Figure 3 Bladder wall interruption
(a,b) and a normal example for
comparison (c) on grayscale
ultrasound.
Easily identifiable
and measurable
myometrium
Myometrium
undetectable
Myometrium
undetectable
Figure 4 Myometrial thinning (a,b)
and a normal example for compari-
son (c) on grayscale ultrasound.
Placental bulge
Figure 5 Placental bulge (a) and a normal example for comparison
(b) on grayscale ultrasound.
Figure 6 Focal exophytic mass (a) and a normal example for
comparison (b) on grayscale ultrasound.
Figure 7 Uterovesical hypervascularity (a) and a normal example
for comparison (b) on color Doppler imaging.
Figure 8 Subplacental hypervascularity (a) and a normal example
for comparison (b) on color Doppler imaging.
Figure 9 Bridging vessels on color
Doppler imaging.
Figure 10 Placental lacunae feeder
vessels on color Doppler imaging.
90°
Figure 11 Intraplacental hypervascularity on three-dimensional
power Doppler: (a) lateral view; (b) basal view. Reproduced from
Shih et al.25 with permission.
Copyright © 2015 ISUOG. Published by John Wiley & Sons Ltd. Ultrasound Obstet Gynecol 2016; 47: 271–275.
274 Collins et al.
of opinions regarding the predictive value of each
descriptor. The unified descriptors were augmented by
images that the expert panel agreed were characteristic;
these images, accompanied by examples of normal
appearance where appropriate, of the unified descriptors
are provided here (Figures 1–11 and S1–S11) and a
description of technical aspects of the sonographic
examination of AIP, with suggestions for obtaining such
images in cases suspicious for AIP, are provided in
Appendix S2.
AIP is a clinically relevant, difficult-to-manage problem
with rising incidence worldwide22. Accurate antenatal
diagnosis, the basis for appropriate risk assessment and
delivery planning, improves maternal outcome12–14, but
is currently dependent on subjective interpretation of
imaging findings. Until now, there has been no agreed
terminology for these findings. We have identified and
analyzed terms commonly used in the literature and
unified them. We propose standardized unambiguous
definitions of these AIP descriptors and accompany them
with characteristic ultrasound images.
These descriptors for AIP should be useful for clinical
use, education, teaching and future research projects.
In addition to using common terminology, describing
precisely the location of the placenta and the part
suspicious for abnormal invasion (the topography of
AIP) should be considered a standard requirement for
describing affected cases.
Maternal mortality and morbidity associated with
AIP are reduced when cases are delivered in a tertiary
referral center with an experienced multidisciplinary
team12–14,23. Referral to such a team depends on the
prenatal diagnosis of AIP by the primary healthcare
providers. By defining clearly the sonographic signs of AIP
we hope to facilitate this referral process. Furthermore, the
rarity of this condition necessitates collaboration between
centers, both nationally and internationally. Ensuring that
all investigators are reporting the same ultrasound findings
when referring to a specific sign will improve homogeneity
of data collection, making results more valid.
Based on these new descriptors we are currently
collecting evidence and expert opinions regarding the
predictive value of these signs, aiming to develop
guidelines for the diagnosis and management of AIP.
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SUPPORTING INFORMATION ON THE INTERNET
The following supporting information may be found in the online version of this article:
Figures S1–S11 Full-size versions of Figures 1–11.
Appendix S1 The 23 studies of pregnancies at risk for invasive placentation analyzed by the European
Working Group on Abnormally Invasive Placenta (EW-AIP) to produce the proposed standardized definitions
of the abnormally invasive placenta imaging descriptors
Appendix S2 Technical aspects to consider when performing an ultrasound scan for AIP markers
Table S1 Wording used in the literature to describe signs for abnormally invasive placenta, grouped according
to ultrasound modality
Table S2 Occurrence of each abnormally invasive placental descriptor in the literature, grouped according to
ultrasound modality
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